Raymond James raised its price target on Knight Therapeutics (GUD.TO) to C$11.50 from C$9.
Analyst Michael W. Freeman maintained an outperform rating on shares of the Canadian speciality pharmaceutical company following its Q2 results.
"We see GUD transitioning from a platform construction story to a diversified commercial execution story, with robust regulatory, market access, and commercial infrastructure investments yielding significant top-line growth across Canada and LATAM (FY26+), Freeman said. "We think GUD will drive meaningful operating leverage and margin expansion (FY27+) as its deep pipeline translates into new launches."
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)